Zetia
E468959
Zetia is a prescription cholesterol-lowering medication (generic name ezetimibe) that reduces intestinal absorption of cholesterol and is marketed by Merck & Co.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Zetia canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4784891 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
Target entity: Zetia Context triple: [Merck & Co., notableDrug, Zetia]
-
A.
Lamotrek
Lamotrek is a small atoll in the Federated States of Micronesia known for its traditional seafaring culture and navigational expertise.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Target entity: Zetia Target entity description: Zetia is a prescription cholesterol-lowering medication (generic name ezetimibe) that reduces intestinal absorption of cholesterol and is marketed by Merck & Co.
-
A.
Lamotrek
Lamotrek is a small atoll in the Federated States of Micronesia known for its traditional seafaring culture and navigational expertise.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
Statements (39)
| Predicate | Object |
|---|---|
| instanceOf |
cholesterol-lowering medication
ⓘ
lipid-lowering agent ⓘ pharmaceutical drug ⓘ |
| actsOn | small intestine ⓘ |
| canBeCombinedWith |
atorvastatin
ⓘ
simvastatin ⓘ statins ⓘ |
| hasActiveIngredient | ezetimibe ⓘ |
| hasATCCode | C10AX09 ⓘ |
| hasCommonSideEffect |
abdominal pain
ⓘ
diarrhea ⓘ fatigue ⓘ headache ⓘ |
| hasDosageForm | tablet ⓘ |
| hasDrugClass | cholesterol absorption inhibitor ⓘ |
| hasGenericName | ezetimibe NERFINISHED ⓘ |
| hasIndication |
patients not adequately controlled with statins alone
ⓘ
patients with primary hyperlipidemia ⓘ |
| hasPregnancyCategory | C (US, historical) ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousSideEffect |
elevated liver enzymes
ⓘ
myopathy ⓘ rhabdomyolysis ⓘ |
| hasTypicalDose | 10 mg once daily ⓘ |
| isContraindicatedIn |
patients with active liver disease
ⓘ
patients with unexplained persistent elevations in hepatic transaminases ⓘ |
| isMarketedBy |
MSD
NERFINISHED
ⓘ
Merck & Co. NERFINISHED ⓘ |
| isUsedWith | dietary therapy ⓘ |
| mayIncrease | HDL cholesterol levels ⓘ |
| mayReduce | triglyceride levels ⓘ |
| reduces |
LDL cholesterol levels
ⓘ
intestinal absorption of cholesterol ⓘ total cholesterol levels ⓘ |
| targets | NPC1L1 transporter NERFINISHED ⓘ |
| treats |
homozygous familial hypercholesterolemia
ⓘ
homozygous sitosterolemia ⓘ hypercholesterolemia ⓘ primary hyperlipidemia ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Subject: Zetia Description of subject: Zetia is a prescription cholesterol-lowering medication (generic name ezetimibe) that reduces intestinal absorption of cholesterol and is marketed by Merck & Co.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.